Rainmed Medical (HKSE:02297) EBIT: HK$-86.58 Mil (TTM As of Dec. 2025)


HKSE:02297 Rainmed Medical Ltd HKSE:02297
49 GF Score
Price HK$0.22
GF Value HK$0.08
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Rainmed Medical EBIT?

Rainmed Medical HKSE:02297 49 EBIT is HK$-86.58 Mil as of Dec. 2025. GuruFocus rates HKSE:02297 with a GF Score™ of 49/100 and a GF Value™ of HK$0.08 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Rainmed Medical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-50.68 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-86.58 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rainmed Medical's annualized ROC % for the quarter that ended in Dec. 2025 was -23.00%. Rainmed Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -38.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Rainmed Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -53.85%.

Rainmed Medical  (HKSE:02297) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Rainmed Medical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-85.648 * ( 1 - 0.1% )/( (332.635 + 411.512)/ 2 )
=-85.562352/372.0735
=-23.00 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=551.173 - 60.542 - ( 219.429 - max(0, 105.581 - 263.577+219.429))
=332.635

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=602.628 - 164.728 - ( 169.333 - max(0, 202.424 - 228.812+169.333))
=411.512

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Rainmed Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-101.362/( ( (212.376 + max(-24.631, 0)) + (311.177 + max(-126.161, 0)) )/ 2 )
=-101.362/( ( 212.376 + 311.177 )/ 2 )
=-101.362/261.7765
=-38.72 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23.506 + 12.475 + 8.167) - (60.542 + 0 + 8.237)
=-24.631

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.444 + 12.543 + 39.37) - (164.728 + 0 + 14.79)
=-126.161

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Rainmed Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-86.583/160.785
=-53.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rainmed Medical EBIT Related Terms

Rainmed Medical EBIT Historical Data

* Premium members only.

The historical data trend for Rainmed Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rainmed Medical EBIT Chart

Rainmed Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -777.33 -1,508.29 -126.64 -122.10 -86.97

Rainmed Medical Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -74.35 -45.20 -77.27 -35.90 -50.68

HKSE:02297 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Rainmed Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rainmed Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rainmed Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rainmed Medical's EV-to-EBIT falls into.


HKSE:02297
49GF Score
Rainmed Medical Ltd HKSE:02297
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rainmed Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-86.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-86.58 Mil mean?
Rainmed Medical (HKSE:02297) has a EBIT of HK$-86.58 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rainmed Medical.
Is Rainmed Medical's EBIT too high?
Rainmed Medical's current EBIT is HK$-86.58 Mil. Overall, Rainmed Medical has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rainmed Medical's EBIT compare to ABT and SYK?
Rainmed Medical's EBIT of HK$-86.58 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rainmed Medical. Rainmed Medical's current EBIT is HK$-86.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainmed Medical stock overvalued right now?
Based on GuruFocus' analysis, Rainmed Medical (HKSE:02297) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.22 — trading 175% above its estimated fair value. The current EBIT is HK$-86.58 Mil. Rainmed Medical's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Rainmed Medical (HKSE:02297), the current EBIT is HK$-86.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rainmed Medical (HKSE:02297) Overvalued in 2026?

Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued. The current stock price of HK$0.22 is trading 175% above its estimated GF Value™ of HK$0.08. GuruFocus considers Rainmed Medical to be Significantly Overvalued.

Key valuation signals for HKSE:02297:

  • EBIT: HK$-86.58 Mil
  • GF Value™: HK$0.08 vs. price of HK$0.22 (175% above fair value)
  • GF Score™: 49/100 with 9 warning signs

No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rainmed Medical Business Description

Address No. 99, Jinji Lake Avenue, Room NW-05-502, Building 31, Nanopolis Suzhou, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
49GF Score

Get the complete analysis for HKSE:02297

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.22
Price
HK$0.08
GF Value